Cancer therapeutics inspired by defense mechanisms in the animal kingdom
Open Access
- 30 March 2020
- journal article
- research article
- Published by Wiley in Evolutionary Applications
- Vol. 13 (7), 1681-1700
- https://doi.org/10.1111/eva.12963
Abstract
No abstract availableKeywords
This publication has 115 references indexed in Scilit:
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Bee venom suppresses PMA-mediated MMP-9 gene activation via JNK/p38 and NF-κB-dependent mechanismsJournal of Ethnopharmacology, 2010
- Annexin A2 Is a Molecular Target for TM601, a Peptide with Tumor-targeting and Anti-angiogenic EffectsOnline Journal of Public Health Informatics, 2010
- Antineoplastic Agents. 573. Isolation and Structure of Papilistatin from the Papilionid Butterfly Byasa polyeuctes termessaJournal of Natural Products, 2010
- Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall‐cell lung cancer, or pancreatic cancerCancer, 2009
- Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growthJCI Insight, 2009
- Inhibition of Tumor‐Cell Invasion with Chlorotoxin‐Bound Superparamagnetic NanoparticlesSmall, 2009
- Inhibition of lung tumor colonization and cell migration with the disintegrin crotatroxin 2 isolated from the venom of Crotalus atroxToxicon, 2008
- A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimensBritish Journal of Cancer, 2007
- A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancerBritish Journal of Cancer, 2006